Epigral Share Price Falls 7.29% After Q2FY26 Profit Declines 36% YoY to ₹51 Crore

Ahmedabad, November 10: Epigral share price witnessed negative investor demand today as it reported a fall of 36% in its net profit YoY at ₹51 crore. At the market close today, Epigral share price ended 7.29%, or 120.10 points lower at ₹1,528. The shares of Epigral made an intraday high of ₹1,669.40 and an intraday low of ₹1,511.40. The traded volume for the shares stood at 1.68 lakh shares, with the company’s market cap at ₹7,110 crore. The shares have their 52-week high at ₹2,242.55 and their 52-week low at ₹1,502.35.

Epigral Limited (NSE: EPIGRAL | BSE: 543332) is an Indian company that is engaged in the manufacturing and selling of Chlor-Alkali and its derivatives. The company was established in 2007, and is headquartered in Ahmedabad, Gujarat.

Epigral Limited Q2FY26 and Half-yearly Financial Highlights

The company reported total revenue of ₹589 crore in Q2FY26, which was 7% lower YoY compared to ₹632 crore in Q2FY25, and 4% lower QoQ from ₹615 crore in Q1FY26. Gross profit was at ₹220 crore, a 16% YoY decline and a 13% QoQ decline. EBITDA stood at ₹132 crore, down 26% YoY and 19% QoQ. EBITDA margin was at 23%. Profit Before Tax (PBT) was ₹70 crore, a 43% YoY decline and 34% lower QoQ. Profit After Tax (PAT) came in at ₹51 crore, also lower by 36% YoY and 68% QoQ. This was partly impacted by a one-time deferred tax adjustment benefit in the previous period. The PAT margin was 9%, compared to 13% in Q2FY25. EPS for Q2FY26 was ₹11.9, down from ₹19.4 last year and ₹37.2 last quarter.

For the first half of FY26, the company reported total revenue of ₹1,204 crore, which is 6% lower YoY, compared to ₹1,285 crore in H1FY25. Gross profit for the period was ₹472 crore, down 10% YoY. EBITDA also declined by 17% YoY, to ₹296 crore, compared to ₹355 crore in the same period last year. PBT for H1FY26 stood at ₹177 crore, marking a 30% decline YoY. PAT increased to ₹212 crore, a 27% YoY increase. EPS for H1FY26 was ₹49.1, compared with ₹40.1 in H1FY25, showing a 22% YoY improvement.

Investor Takeaway for Epigral Limited

The Q2FY26 financial performance was weak, as revenue, gross profit, and EBITDA declined both year-on-year and quarter-on-quarter. The weak financial results were the main reason for a lower investor sentiment today, leading to a heavy selloff. Investors will now hope that the company can post better numbers for the next quarter.

REF: https://nsearchives.nseindia.com/corporate/MFL_10112025132943_EpigralEarnPrest.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations